This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Idiopathic Pulmonary Fibrosis
and you are
between 18 and 75
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The investigators aim to evaluate the role of 68Ga-DOTA-NOC PET/CT in patients with idiopathic pulmonary fibrosis, in particular in patients with a diagnosis of IPF/UIP (idiopathic pulmonary fibrosis, diagnosed based in the American Thoracic Society and European Respiratory Society criteria) and in forms of NSIP (non-specific interstitial pneumonia). PET/CT imaging data will be compared with HRCT (high-resolution computed tomography) findings to assess disease extension, early disease detection and to non-invasively detect somatostatin receptors expression at lung level in these patients, with potential therapeutic implications.

Provided treatments

  • Procedure: 68Ga-DOTA-NOC PET/CT

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01321996. The sponsor of the trial is Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi and it is looking for 29 volunteers for the current phase.
Official trial title:
Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis